Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1992 Jun 1;175(6):1623-33.
doi: 10.1084/jem.175.6.1623.

An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7)

Affiliations
Comparative Study

An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7)

W Held et al. J Exp Med. .

Abstract

The classical minor lymphocyte stimulating (Mls) antigens, which induce a strong primary T cell response in vitro, are closely linked to endogenous copies of mouse mammary tumor viruses (MMTV). Expression of Mls genes leads to clonal deletion of T cell subsets expressing specific T cell receptor (TCR) V beta chains. We describe the isolation and characterization of a new exogenous (infectious) MMTV with biological properties similar to the Mls antigen Mls-1a. In vivo administration of either Mls-1a-expressing B cells or the infectious MMTV (SW) led to an increase of T cells expressing V beta 6 followed by their deletion. Surprisingly, different kinetics of deletion were observed with the exogenous virus depending upon the route of infection. Infection through the mucosa led to a slow deletion of V beta 6+ T cells, whereas deletion was rapid after subcutaneous infection. Sequence analysis of the open reading frames in the 3' long terminal repeat of both this exogenous MMTV (SW) and of Mtv-7 (which is closely linked to Mls-1a) revealed striking similarities, particularly in the COOH terminus, which has been implicated in TCR V beta recognition. The identification of an infectious MMTV with the properties of a strong Mls antigen provides a new, powerful tool to study immunity and tolerance in vivo.

PubMed Disclaimer

References

    1. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6293-6 - PubMed
    1. J Exp Med. 1989 May 1;169(5):1703-19 - PubMed
    1. J Natl Cancer Inst. 1978 Oct;61(4):1165-9 - PubMed
    1. Int J Cancer. 1975 Dec 15;16(6):922-31 - PubMed
    1. Eur J Cancer. 1978 Oct;14(10):1137-47 - PubMed

Publication types

MeSH terms

Substances